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Abstract: Alzheimer’s disease (AD) is an incurable age-related neurodegenerative disorder characterized by profound 
memory dysfunction. This bellwether symptom suggests involvement of the hippocampus -- a brain region responsible for 
memory formation -- and coincidentally an area heavily burdened by hyperphosphorylated tau and neuritic plaques of 
amyloid beta (A). Recent evidence suggests that pre-fibrillar soluble A underlies an early, progressive loss of synapses 
that is a hallmark of AD. One of the downstream effects of soluble A aggregates is the activation of the phosphatase cal-
cineurin (CaN). This review details the evidence of CaN hyperactivity in ‘normal’ aging, models of AD, and actual disease 
pathogenesis; elaborates on how this could manifest as memory impairment, neuroinflammation, hyperphosphorylated 
tau, and neuronal death. 
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1. INTRODUCTION  
  Calcineurin (CaN), also known as protein phosphatase 
2B (PP2B), is a calcium (Ca
2+)-sensitive serine/threonine 
phosphatase highly expressed in the central nervous system 
(CNS) and originally isolated from mammalian brain [1]. 
Structurally, CaN is a heteromeric protein comprised of a 
catalytic subunit (CaNA) and a regulatory subunit (CaNB) 
[2]. While the catalytic site of CaNA is similar to protein 
phosphatase-1 (PP1) and protein phosphatase-2A (PP2A), 
the regulatory CaNB shares 30-50% sequence homology 
with calmodulin (CaM) [3]. Among this family of related 
phosphatases CaN is singular in that it is directly activated 
by CaM, making it uniquely and exquisitely responsive   
to Ca
2+ fluctuation [4]. Relatively unaffected by traditional 
phosphatase inhibitors, CaN is sensitive to the immuno- 
suppressants cyclosporine A and FK506 when they are 
bound to their respective immunophilins cyclophilin A and 
FKBP12 [5]. The use of these compounds, coupled with   
antisense RNA technology and transgenic models have   
only recently allowed investigation into the roles of CaN in 
cellular signaling. 
  The designation “calcineurin” reflects the initial belief 
that it was uniquely expressed in neurons, where it is present 
in such high levels as to comprise 1% of total neural protein 
[2]. In fact, this important phosphatase -- conserved from 
yeast to man -- is present in a diverse group of cell types 
where it responds to the binding of activated CaM in multi-
ple ways, including modulating immune responses [6],   
influencing muscle formation and remodeling [7], neuronal 
plasticity [8-9], and cell death [10-11]. Due to the promiscu-
ous tendencies of the phosphatase, Ca
2+ entry and subsequent 
CaN activation signals powerful cellular processes impacting 
cell survival and growth. Included on the list of CaN   
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substrates are the phosphorylated forms of nuclear factor of 
activated T- cells (NFAT) [12]; cAMP response element 
binding (CREB) [8]; PP1 [8, 13]; microtubule-associated 
protein tau [14-15]; glycogen synthase kinase-3 beta (GSK-
3) [16, 17]; and Bcl-2 associated death protein (BAD) [10, 
11]. The effects of CaN hyperactivity on these downstream 
proteins and the evidence for their involvement in AD 
pathogenesis will be the focus of this review.  
2. CALCINEURIN AND SYNAPTIC FUNCTION 
  This section will briefly delineate the intimate relation-
ship between CaN signaling and neuronal excitability [rev. in 
3, 9]. CaN is able to dephosphorylate a number of ion chan-
nels, including L-type Ca
2+ channels [18], potassium (K
+) 
channels [19], and voltage-gated sodium (Na
+) channels [20-
21]. Through its impact on ion channels, CaN activation im-
pacts the basal excitability of neurons.  
  CaN also exerts powerful effects on synaptic transmis-
sion in both the pre- and post-synaptic compartments. For 
instance, CaN has been reported to affect the release of neuro- 
transmitters from the pre-synaptic compartment by negatively  
regulating exocytotic release of glutamate. This outcome is 
likely due to the ability of CaN to dephosphorylate synapsin 
I, a phosphoprotein that tethers neurotransmitter-containing 
vesicles to the cytoskeleton [22]. When phosphorylated, the 
synapsin-associated vesicles are moved from the reserve 
vesicle pool to those ready to be released [23]. Therefore, 
CaN activation could theoretically reduce the amount of   
neurotransmitter released into the synapse. In addition,   
CaN signaling controls the speed of synaptic endocytosis, via 
its effect on the dephosphorylation of endocytotic proteins 
[24].  
  The phosphatase is also involved in post-synaptic events. 
CaN has been demonstrated to dephosphorylate the N-
methyl-D-aspartate receptor (NMDA-R), which serves as a 
signal for the receptor gate to close. In this way, CaN activity 
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and lower open channel probability [25, 26]. CaN is known 
to enhance or prolong the desensitization period of   
other ligand-gated channels, including -aminobutyric acid 
(GABA) [27, 28], serotonin [29], and acetylcholine receptors 
[30].  
  Thus, CaN is intimately involved in a number of   
pathways that modulate neuronal excitability and synaptic 
activity. Dysregulation of this complex system would likely 
have far-reaching consequences on synaptic connectivity.  
3. CALCINEURIN AND MECHANISMS OF MEMORY  
  Given the initial impairments of memory, cognition, and 
concentration that mark early stage AD, this section will 
introduce the normal role of CaN in the physiological   
processes of memory. Long-term potentiation (LTP) is widely 
held to be the molecular basis of learning and memory [31]. 
The phenomenon of LTP was first described in the live   
rabbit hippocampus, where a brief tetanic burst of artificial 
electrical stimuli applied to the perforant pathway resulted in 
enhanced hippocampal neuronal transmission when a single 
shock was administered hours later [32]. Although the rabbit 
brain was not actually encoding memories during these   
sessions, long-lasting potentiation following repetitive   
neuronal firing was quickly identified as a putative mechanism 
of the learning process. LTP can be divided into “early” and 
“late” stages, the first of which involves the phosphorylation 
or membrane insertion of the existing pool of proteins [33], 
and the latter requires gene transcription and synthesis of 
new proteins [34].  
  One piece of cellular machinery necessary for both stages 
of LTP expression was determined to be the NMDA-R.   
Hippocampal pathways are enriched with these specialty ion 
channels, which become operational after an initial membrane 
depolarization sufficient to remove the magnesium block 
from the pore that allows the entry of Ca
2+. In this way, 
NMDA-Rs act as coincidence detectors, opening only in 
response to bursts of synaptic transmission that exceed   
baseline neuronal firing. This allows for Ca
2+entry that is 
activity and temporally specific, occurring as rapid pulses   
in the microsecond to millisecond range [35]. Subsequent 
Ca
2+ binding to CaM results in the activation of downstream 
kinases and phosphatases, including Ca
2+/calmodulin-
dependent protein kinases (CaMKs) and CaN. Parallel   
phosphorylation pathways lead to the activation of CREB; 
pCREB is able to translocate to the nucleus and transcribe 
genes that produce proteins necessary for synaptic   
maintenance and formation [8].  
  A proposed allosteric model suggests that CaM is more 
likely to activate either CaN or CaMKs depending on local 
Ca
2+ concentration [36]. Intense yet confined and transient 
Ca
2+ increases – such as those through NMDA-Rs following 
tetanic stimulation – initially results in the preferential   
activation of CaMKII within the dendritic spines. However, as 
Ca
2+ decreases, but before it returns to baseline, CaM is more 
likely to bind and activate CaN [36]. Via dephosphorylation 
of the dopamine- and c-AMP regulated phosphoprotein of 
Mr 32,000 (DARPP-32), CaN activates PP1 dephosphoryla-
tive capabilities, thus indirectly promoting PP1-dependent 
CREB dephosphorylation (inactivation) [37, 38]. PP1 also 
dephosphorylates CaMKII, consequently decreasing its 
kinase activity towards ion channels until the next wave of 
Ca
2+ entry [13]. Such a setup allows for bidirectional synaptic 
plasticity, where a shift in Ca
2+ levels serves as the switch 
between synapse growth (positive) and synapse pruning 
(negative). The latter is likely accomplished by long-term 
depression (LTD), an activity-dependent decrease in synaptic 
efficacy that is typically induced by a more modest but   
protracted rise in Ca
2+ [39, 40]. LTD is facilitated through 
CaN activity and is thought to allow for more efficient neural 
storage.  
  The precise role of CaN in learning and memory has been 
probed by overexpressing, inhibiting, and knocking down the 
phosphatase. Targeted overexpression of CaN in the fore-
brain of mice impaired the transition from short-term to 
long-term memory as well as an intermediate form of LTP 
[41, 42]. Conditional genetic knockout of CaN in mouse 
forebrain resulted in impairment within a specific subset of 
hippocampal-dependent tasks including working and episodic 
memory [43]. However, knockdown of CaN expression   
with antisense oligonucleotides results in the facilitation   
of LTP and improved performance in the Morris water   
maze [44]. Similarly, partial CaN inhibition with a tunable, 
inducible rtTA system also facilitated LTP and performance 
in a hippocampal-dependent behavioral test [45]. Collectively, 
these studies suggest that equilibrium between positive and 
negative plasticity is critical for proper cognitive function; 
and that an appropriate level of CaN activity is central to this 
balance.  
4. CALCINEURIN AND AGING  
  It is well recognized that aging has a profound effect on 
the welfare of neurons in the central nervous system (CNS). 
As part of a larger network not easily reproduced, post-
mitotic CNS neurons are remarkably long-lived in comparison 
to other cell types such as epithelia. Only in the past forty 
years was it acknowledged that neurogenesis occurs in the 
adult brain, most of the neurons do not actively divide past 
puberty. An exception is the dentate gyrus of the hippocampus, 
where neurogenesis continues post-natally into adulthood 
[46, 47]. Although there is continued proliferation in certain 
brain regions, the average neuron in the aged brain has been 
exposed to decades of oxidative insults.  
  The brain is further disadvantaged by its high-energy 
metabolism and low endogenous anti-oxidant defenses [48]. 
Aging exacerbates these unfavorable conditions: evidence   
of increased oxidative stress and reduced mitochondrial 
function have been extensively documented in the aged   
brain [49]. Both of these factors decrease cellular ability   
to tightly regulate Ca
2+ Fig. (1). Perturbation in Ca
2+ levels 
are particularly troublesome for neurons, as numerous   
cellular processes are governed either by intracellular Ca
2+  
or downstream kinases and phosphatases, including LTP   
and LTD. Indeed, strict governance of Ca
2+ is especially 
critical at the synapses of hippocampal pathways. These 
connections are borne out of intense, local Ca
2+  entry  
into dendritic spines containing high concentrations of 
NMDA-Rs. Positive and negative regulators of plasticity, 
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neurons. Therefore, these networks responsible for learning 
and memory are particularly vulnerable to functional altera-
tions with increasing age.  
  For twenty-five years it has been known that neurons 
from the aged brain have altered Ca
2+ currents in comparison 
to young [50], possibly due to increased numbers of voltage-
gated Ca
2+ channels (VGCCs) [51]. More recent evidence 
suggests that Ca
2+ entry through VGCCs augments a secon-
dary Ca
2+ flux from the endoplasmic reticulum to the cytosol 
through ryanodine receptors, and that this occurs to a greater 
degree in aged hippocampal neurons [52]. Regardless of the 
mechanism of Ca
2+ increase, CaN activity is upregulated in 
the aging hippocampus. Impaired performance in the Morris 
water maze mirrors elevated CaN activity and cytosolic CaN 
expression in the aged rat hippocampus. These increases are 
paralleled by enhanced dephosphorylation of CaN-substrates 
BAD and CREB, as well as augmented activity of PP1 [53]. 
Electrophysiological studies suggest that LTD predominates 
over LTP in the aged rat brain, but that this is antagonized by 
CaN inhibition [54]. CaN may also exacerbate the already 
dysregulated Ca
2+ homeostasis in aged brain; CaN modulates 
the activity of VGCCs in hippocampal cultures and inhibi-
tion with FK506 blocks the activity of these channels [55]. 
New studies in partially dissociated hippocampal “zipper” 
slices from young, middle-aged, and old rats show that   
this phenomenon also occurs in vivo, and suggests that CaN 
may directly activate VGCCs. Viral-mediated delivery of 
activated CaN to primary hippocampal neurons increased 
VGCC activity [56]. These results are attributable to enhanced  
“neuronal CaN activity.” However, immunohistochemical 
analyses of aged murine hippocampi show intense CaN 
staining in activated astrocytes [57], providing a possible 
role for CaN hyperactivity in triggering astrogliosis and   
inflammatory pathways.  
5. CALCINEURIN AND A 
  This section will discuss how certain species A are able 
to hyperactivate CaN in models of AD. Data gathered   
from  in vitro, ex vivo, and in vivo studies illustrates how 
dephosphorylation of CaN substrates can impact gene trans- 
cription, cell death, ion channel activity, and synaptic integrity.  
  The original “Amyloid Hypothesis” predicted that altered 
processing or clearance of A resulted in plaque deposition 
and AD symptoms, but this proposal has undergone a   
revision in recent years. Although insoluble, fibrillar A was 
initially believed to be central to disease pathogenesis, the 
latest evidence has indicated that soluble oligomeric A is 
behind the earliest cognitive deficits [58]. Indeed, the pro- 
position that small A aggregates are able to affect cognition 
via  synaptotoxic action has received robust experimental 
confirmation in the last decade. Oligomeric species have 
been shown to preferentially accumulate at the synapse in 
cultured hippocampal neurons [59, 60], where they are able 
to alter the shape, size, and protein composition of the   
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Calcineurin in the aging AD brain. The aged brain is susceptible to hyperactivation of CaN and downstream consequences due to its 
decreased ability to regulate intracellular Ca
2+ levels. The additional insult of A oligomers further disrupts synaptic homeostasis, resulting 
in a subtle, prolonged increase in calcium that facilitates the expression of LTD. Activation of CaN by CaM disrupts the phosphatases inter-
action with tau, possibily leading to tau hyperphosphorylation [92]. CaN also mediates the dephosphorylation of several cellular proteins: 
pCREB [8], pNFAT [81], p-PP1 [13, 53], p-GSK-3 [16], and pBAD [10, 11]. This could putatively explain four observations in AD models 
and pathogenesis; synaptic protein loss, neuroinflammation (neuronal and astrocytic), decreased neurotransmission, hyperphosphorylated 
tau, and cell death. Therefore, inhibition of CaN or the promotion of positive plasticity may serve as viable therapeutic strategies for combat-
ing early stage AD impairment. 688    Current Neuropharmacology, 2011, Vol. 9, No. 4  Reese and Taglialatela 
dendritic spines [61]. Why oligomers are attracted to the 
synapse is not well understood, but several hypotheses have 
been suggested, such as influence of metal ion concentration 
[62]. 
 A  disrupts the functionality as well as the structure of 
the synapse. Application of oligomeric A counteracts the 
increase in AMPA phosphorylation that normally occurs 
following tetanic stimulation of rat hippocampal slices, pre-
cluding the expression of early LTP [63]. Synthetic A in-
hibits late phase LTP in a CaN-dependent fashion during 
electrophysiological recordings [64, 65]. Soluble oligomeric 
A from several sources (synthetic, cell culture, human brain 
extracts) facilitates electrically evoked LTD and causes   
a 33% reduction of dendritic spine density in organotypic 
hippocampal cultures. Both outcomes were preventable by 
the CaN inhibitor FK506 [66]. Collectively, these studies 
hint that A-mediated activation of CaN promotes LTD   
over LTP. As discussed in previous sections, this important 
balance between positive and negative plasticity is already 
perturbed in the normal aged brain. Further exacerbation   
by oligomeric A could putatively explain the pathological 
synaptic loss believed to underlie the early symptoms of AD.  
  The effect of A on CaN activity can be explained by  
its ability to perturb intracellular Ca
2+ Fig. (1). Certain   
aggregate species are able to act as Ca
2+ channels in   
synthetic bilayer membranes [67], and A is hypothesized to 
interact with several membrane receptors, including 
NMDARs [68], alpha-7 nicotinic receptors [69], or meta- 
botropic glutamate receptors [70]. Given its unknown   
function and cell surface receptor-like structure, it is possible 
that oligomers bind to and signal through full-length   
amyloid precursor protein (APP) [71]. Live Ca
2+ imaging   
of SY5Y human neuroblastomas demonstrates that oligomeric 
A is the only species that appreciably augments the   
concentration of cytosolic Ca
2+ by disrupting the cellular 
membrane. This increase was reduced but not abolished 
when the experiment was performed in Ca
2+ free conditions, 
with 30% of the rise coming from internal stores [72].   
Whatever the source, these studies suggest that only   
oligomers should be capable of upregulating CaN activity, via 
the Ca
2+ increase. Indeed, only oligomers raise intracellular 
Ca
2+, CaN hyperactivity, and CaN dependent cell death in 
cell cultures [73, 74]. 
 Multiphoton  Ca
2+ imaging of AD mouse models has   
revealed the extent of Ca
2+ dysregulation provoked by A  
in vivo. In aged double transgenic mice (APP/PS1) with   
cortical plaques, 20% of the neurites contained elevated   
resting Ca
2+  levels, much greater than the young double   
mutants and significantly higher than the 5% increase in 
aged wild-type mice or single mutants. Furthermore, Ca
2+ 
overload correlated with the proximity to A plaques.   
An observation coincident with increased resting Ca
2+ was 
neuritic “beading” – a morphological change indicative   
of neuronal stress. This effect was partially attenuated   
by systemic treatment with FK506, again indicating that 
structural changes downstream of Ca
2+ overload are mediated 
in part by CaN [75]. Indeed it was later found that A  
induces loss of dendritic spines, simplification of dendritic 
arborization and neuritic dystrophies through a CaN/NFAT-
dependent mechanism [76].  
  CaN hyperactivity alters the ability of neurons to turn on 
protein synthesis that normally occurs during late-stage LTP. 
In vitro experiments have shown that pCREB levels as well 
as its transcriptional activity are diminished in a CaN-
dependent fashion following treatment with oligomeric A. 
The same study reported that hippocampal pCREB immuno- 
reactivity is reduced in the Tg2576 murine model of AD,   
but is restored by treatment with FK506 [74]. This   
animal model produces high levels of A and first displays 
behavioral impairments at five months of age, coincident 
with the onset of elevated CaN activity [77]. Acute inhibition 
of CaN by FK506 improved the performance of these   
animals on a hippocampal-dependent fear conditioning   
paradigm [77] and novel object recognition as well [78]. 
Wild-type mice given a single intracerebroventricular   
injection of oligomeric A exhibited similar deficits in the 
fear conditioning paradigm, again this was reversible with 
FK506 [65]. Together, these studies suggest that some of   
the behavioral impairments in AD mouse models could be 
explained by CaN hyperactivity and its subsequent effects on 
pCREB and synaptic plasticity.  
  The viability of neurons is also affected by A, with CaN 
playing a central role. Application of A has long been 
known to induce apoptosis in neuronal cultures [79]. This 
stringently controlled process is distinct from necrosis and 
necessitates the involvement of cellular signaling. One such 
pathway that leads to an apoptotic outcome is the CaN-
mediated dephosphorylation of pBAD. Dephosphorylated 
BAD is able to dissociate from scaffolding proteins and 
translocate to the mitochondria, where it forms pro-apoptotic 
dimers with the protein Bcl-X(L), triggering cytochrome c 
release, thus initiating programmed cell death [10]. In SY5Y 
human neuroblastoma cells treated with increased concen- 
trations of oligomeric A there is a dose-dependent decrease 
in pBAD levels [74]. Treatment of primary cortical neurons 
with synthetic A peptides increases CaN activity; reduces 
the level of phosphorylated BAD; and increases the amount 
of BAD found in the mitochondria [80]. These effects on 
cortical neurons were attenuated by the CaN inhibitor FK506, 
suggesting that some of the neurodegeneration seen in AD 
may be due to the ability of CaN to induce apoptosis via BAD.  
  As mentioned previously, CaN also dephosphorylates 
NFAT, allowing its translocation to the nucleus where it 
promotes the transcription of genes involved in cytokine 
production and inflammation [12]. Application of oligomeric 
A increases NFAT activation in primary rat astrocyte   
cultures. This treatment also causes a significant reduction in 
excitatory amino acid transporter 2 (EAAT2) protein levels 
in astrocyte cultures, theoretically leaving extracellular   
glutamate levels high and increasing the likelihood of   
excitotoxic cell death. Inhibition of NFAT prevented A-
mediated elevation in glutamate and cell death [81]. 
  The lines of evidence described above conceptually link 
A-mediated Ca
2+  dysregulation, CaN hyperactivation,   
decreased synaptic plasticity, cell death, and neuro- 
inflammation. However, the models tested against the CaN 
hyperactivity hypothesis with relatively high levels of aggre-
gated recombinant A (the longer and stickier 42-amino-acid 
form), genetic overexpression of mutated APP prone to the 
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enzymes termed presenilins (PS1 and PS2) isolated from a 
few kindreds with rare forms of familial AD. While this   
research has shed considerable light on possible mechanisms 
of A synaptotoxicity and neuronal death, it is important to 
examine evidence that does not rely exclusively on atypical 
mutations of APP or presenilins, as sporadic, late-onset AD 
accounts for more than 90% of all cases with risk increasing 
dramatically with age. 
6. CALCINEURIN AND TAU  
  In addition to A plaques, hyperphosphorylated tau is the 
other pathological signature of AD [82]. Tau is the major 
microtubule-associated protein (MAP), and is responsible for 
modulating the assembly and organization of microtubules, 
which facilitate intraneuronal transport [83]. Phosphorylation 
of tau decreases its affinity for the microtubules and   
the subsequent disassociation of tau increases the rate of   
microtubule depolymerization [84-85]. Thus, aberrant tau   
phosphorylation results in a loss of endogenous tau functions, 
as well as a toxic gain of function, where pathological tau 
assembled into paired-helical filaments (PHFs) sequesters 
normal tau [rev. in 86]. 
  The hyperphosphorylated tau tangles that overwhelm the  
AD brain were conjectured to be the result of an imbalance  
between the kinases and phosphatases that interact with tau  
[86]. CaN was one of the phosphatases demonstrated to   
dephosphorylate tau, in vitro [14-15, 87]. At the same time,  
two independent groups reported that tangle-containing   
neurons and neurons surrounding plaques in AD brain   
showed strong CaN immunoreactivity [88, 89]; promoting   
the hypothesis that CaN modulated tau phosphorylation and  
suggested that decreased CaN activity may be in part   
responsible for hyperphosphorylation of tau [87]. Calcipressin,  
an endogenous CaN inhibitor, is found at high levels in AD  
brain, seemingly supporting the hypothesis that CaN   
phosphatase activity is decreased [90, 91]. For these reasons  
CaN was originally theorized to be down-regulated during AD  
pathogenesis, and that one of the downstream consequences  
was the hyperphosphorylation of tau. However, more recent  
evidence suggests that this view may be erroneous.  
  It has been demonstrated that both the A and B subunits 
of CaN associate directly with tau [92]. However, the bind-
ing of CaM to CaN impairs the binding between CaN and 
tau. These results suggest that CaN interacts with tau in basal 
Ca
2+ conditions. So, when intracellular Ca
2+ rises, activated 
CaM binds to CaN, disrupting its interaction with tau, and 
CaN’s ability to dephosphorylate tau is impaired. In such a 
scenario, an increase in Ca
2+ hyperactivates CaN, which 
would paradoxically result in a decrease in CaN-mediated 
desphosphorylation of tau Fig. (1). CaN is also able to 
dephosphorylate glycogen synthase kinase-3 beta (GSK-3) 
[16]. This activates GSK-3, which is then able to phos-
phorylate tau at the same epitopes that are phosphorylated in 
AD brain [93].  
Relatively few current studies have examined the interplay 
of tau and CaN. As it has become more evident that CaN 
activity is increased, researchers have began to re-explore   
the topic. For example, evidence from hippocampal slice   
cultures demonstrates that dendritic spine pathology requires 
CaN activation and downstream GSK-3 activation but   
amyloid beta-induced and tau-mediated neurodegeneration 
occuring in the cell soma occurs independently of CaN [94]. 
It is likely that additional research using current model   
systems will further clarify the relationship between CaN 
and tau in AD.  
7. CALCINEURIN AND AD 
  This section will describe evidence for CaN hyper- 
activation within the actual disease state. Despite a growing 
amount of information from in vitro,  ex vivo, and animal 
models, the evidence for dysregulation of CaN in actual AD 
brain is still scarce and inconclusive. Although sample sizes 
are much smaller, results from studies of human tissue from 
early and late-onset AD corroborate with those obtained 
from disease models to strengthen the case for CaN hyper- 
activation as a central factor in AD pathogenesis in both   
sporadic and familial AD pathogenesis. 
  Recent studies suggest that CaN is in fact upregulated in 
AD brain. One small study on a small cohort (n = 7) of AD 
cerebral cortex found that in comparison to control brain (n = 5), 
overall phosphatase activity was decreased in AD. Con-
versely, nickel-stimulated increase of CaN activity was signi- 
ficantly higher in the prefrontal, but not sensorimotor cortex 
[95]. An investigation into CaN-mediated dephosphorylation 
of phosphorylated tau in human frontal cortex yielded no 
significant difference between AD and control brains [96]. 
However, this particular study employed Huntington disease 
samples as ‘control’. Such activity assays are only possible 
in rapidly autopsied tissue due to the swift oxidation of CaN 
post-mortem. Unfortunately similar experiments have not 
been done in the hippocampus, to-date. 
  Incubation of brain extract with calpains produces CaN 
that is cleaved at lysine residue 501 as measured by mass 
spectometry. This 57-kDa cleaved version of CaN is elevated 
in AD homogenates from medial-temporal cortex. The   
truncated form maintains the autoinhibitory region, and   
thus is still dependent on CaM to be activated. In the   
presence of CaM, in vitro phosphatase activity is enhanced 
following cleavage [97]. A recent publication reported a 2 
fold increase in the level of a 54-kDa fragment of CaN in the 
nuclear fraction of AD cortex [76]. These results were in 
disagreement with a publication from 2007, which found 
decreased  immunoreactivity for CaN in an immuno- 
histochemical examination of AD frontal cortex. However, 
this study relied on a very small number of AD tissue   
samples (n = 3). Furthermore, when modeling the proposed 
A-mediated CaN decrease in primary neuron lines, a   
very high level of A (10μM) was necessary to obtain a   
significant decrease in CaN [98]. This concentration is 
physiologically irrelevant, and further studies are necessary 
to confirm the reported findings. 
  Downstream of CaN, certain isoforms of NFAT (NFAT1 
and 3) are increased in the nuclear fraction from AD hippo-
campal homogenate. These correlate with levels of soluble 
A as well as Mini-Mental State Exam scores (MMSE), a 
standard measure of cognitive function [82]. Analysis of 
CREB and pCREB levels in human tissue show that amounts 
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[99]. While this publication did not investigate the possible 
involvement of CaN, this report of decreased pCREB is   
circumstantial evidence that fits within the schematic of 
CaN-mediated cognitive dysfunction in AD. 
8. CONCLUSIONS  
  The greatest risk factor for developing AD is increasing 
age. While this is the case for many neurodegenerative con-
ditions and may be a confounded correlation, it does suggest 
that something about aging neurons renders them especially 
susceptible to the ravages of AD. In older organisms,   
the brain is less plastic, in part due to a dysregulation of   
Ca
2+ dynamics. The environment of the aged brain, further 
insulted by the presence of oligomeric A, may result in   
an enhancement of CaN activity sufficient to explicate   
several negative outcomes observable in AD brain:   
decreased neurotransmission, synaptic loss, tau pathology, 
neuroinflammation, and cell death Fig. (1).  
  Therefore, it is prudent to consider the possibility of CaN 
inhibition as a pharmacological target in the development   
of novel AD therapies. FK506 and cyclosporine cause the 
unfortunate side-effect of immunosuppression via  NFAT-
mediated down-regulation of interleukin-2. This is an   
undesirable circumstance for aged patients already contending 
with compromised immune function. Uncompetitive 
NMDA-R antagonists, including memantine, have showed 
some promise at delaying the clinical progression of AD   
but not preventing the outcome [100]. Based on the evidence 
described here, the positive effects following such pharma-
cological regimens may be due to some prevention of Ca
2+ 
entry. More efficacious therapies may require a different 
approach to preventing excessive intracellular Ca
2+,  
regulation of CaM signaling, or perhaps a more precise   
inhibitor of neuronal CaN. 
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